To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Conference Call.” The conference call will be webcast live ...

Vertex Pharmaceuticals said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of mutations of the ...

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") ...

The announcement comes directly from Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated, with the signatory on the report being Jonathan Biller, the Executive Vice President and Chief Legal Officer ...

CNBC’s Jim Cramer delivers his daily Mad Dash. Luigi Mangione, CEO killing suspect, pleads not guilty to state terror and murder charges in Manhattan court Congress ...

On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the ...

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain. The company ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall. Vertex will continue testing ...

Vertex Pharmaceuticals shares fell after the company ... a neurological disorder that causes back and leg pain. The Boston biotechnology company on Thursday said the treatment, suzetrigine ...